Clene

Clene Long-term Debt

The Long-Term Debt of Clene (CLNN) as of Nov 16, 2026 is 13.54 M USD. In the previous year, Long-Term Debt was 15.43 M USD — a change of -12.22% (lower).

Long-term Debt

13.54 MUSD

YoY

-12.22%

Last updated:

Long-Term Debt of Clene is 2025 13.54 M USD. Long-Term Debt of Clene was 2024 15.43 M USD. It decreases by -12.22% lower compared to the previous year.

The Clene Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2019
640,000.00 USD
Jan 1, 2020
1.95 M USD
Jan 1, 2021
14.48 M USD
Jan 1, 2022
19.25 M USD
Jan 1, 2023
7.15 M USD
Jan 1, 2024
15.43 M USD
Jan 1, 2025
13.54 M USD
The Clene Long-term Debt history
YEARLong-term DebtYoY
13.54 MUSD-12.22%
15.43 MUSD+115.69%
7.15 MUSD-62.85%
19.25 MUSD+32.93%
14.48 MUSD+643.15%
1.95 MUSD+204.53%
640,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Long-Term Debt of Clene is 13.54 M USD in 2025.

Long-Term Debt of Clene changed from 15.43 M USD to 13.54 M USD, representing a -12.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Clene since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Clene

All Key Metrics — Clene